-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:12 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment Following Surgical Resection and Platinum-Based Chemotherapy for Patients With Stage IB (T2a ≥4 Centimeters), II, or IIIA Non-Small Cell Lung Cancer (NSCLC)
27 Jan 2023 12:06 GMT
… non-small cell lung cancer following surgery and … Platform (ETOP).
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
CHMP recommends marketing approval for AstraZeneca's Imfinzi plus Imjudo to treat advanced liver and lung cancers
20 Dec 2022 06:19 GMT
… (EU) for advanced liver and lung cancers.
The concurrent positive opinions recommend … with metastatic non-small cell lung cancer in Europe.”
Susan Galbraith, executive … included OS for Imfinzi versus sorafenib, objective response rate and progression …
-
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
08 Dec 2022 21:53 GMT
… metastatic non-small cell lung cancer (NSCLC) without actionable … been previously treated with sorafenib; for patients with …
2 Key Statistics for Lung Cancer. American Cancer Society website … 2022.
3 What is Lung Cancer? American Cancer Society website …
-
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
08 Dec 2022 21:52 GMT
… unmutated metastatic non-small cell lung cancer (NSCLC) who experienced disease progression … have previously been treated with sorafenib.
About Ipsen
Ipsen is a …
-
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
11 Sep 2022 09:56 GMT
… non-small cell lung cancer were treated and … 63.6%.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … been previously treated with sorafenib. This indication is …
-
Five-Year Data for Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Sustained Survival Benefit Versus Chemotherapy Alone in Two Studies for Metastatic Non-Small Cell Lung Cancer (NSCLC)
11 Sep 2022 09:29 GMT
… non-small cell lung cancer were treated and … 63.6%.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … been previously treated with sorafenib. This indication is …
-
The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study
02 Aug 2022 00:04 GMT
… to 15% of all lung cancers.1 SCLC comprises an … limited, such as bevacizumab, sorafenib, sunitinib and so on, … or refractory small cell lung cancer. Lung Cancer. 2013;79(2):137 … patients with relapsed small cell lung cancer. Lung Cancer. 2016;96:108–112. …
-
FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection
13 Jun 2022 11:03 GMT
… development program in lung cancer and is advancing … for placebo.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
06 Jun 2022 11:06 GMT
… to biomarkers.
About Lung Cancer
Lung cancer is the leading cause … node positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … been previously treated with sorafenib. This indication is … squamous non-small cell lung cancer; Checkmate 743–previously …
About
© 1995-2023